Marrow transplantation for severe @entity2150 . Long-term outcome in fifty "untransfused" XXXX .

@entity1 @entity2150 @entity281 @entity2132 @entity204
Fifty @entity1 with severe @entity2150 had no transfusions of blood products until just before marrow transplantation from HLA-identical family members. Of the 50, 42 are still alive 1 to 12 years after transplantation (median, 7 years). By actuarial standards, the 10-year probability of survival is 82%. Of the 42 surviving @entity1 , 37 have Karnofsky performance status scores of 100% and 5 with @entity2132 have scores ranging from 50% to 90% (median, 80%). The 8 @entity204 were caused by @entity281 in 1, graft rejection in 1, @entity2132 in 3, and @entity2132 in 3. All @entity204 occurred within two years after transplantation. The incidence of graft failure was 10%. @entity2132 developed in 14 of 44 @entity1 at risk and @entity2132 , in 15 of 41. Risk factors for development of @entity2132 included increased age (p = 0.008) and presence of @entity2132 (p = 0.001). The only factor associated with increased risk of @entity204 was development of @entity2132 (p = 0.05). Results of this study extend our previous finding that @entity1 with severe @entity2150 who have transplants before the onset of transfusion-induced sensitization have an excellent probability of long-term survival and a normal life.
